Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement
In this cohort study using a target trial emulation, a higher proportion of weight loss after initiating antiobesity medications within 1 year was associated with a lower risk of 5-year and 10-year revision among patients with obesity undergoing joint replacement. These results suggest that antiobesity medication use, with relatively safe and sustainable weight loss, may be an effective strategy for improving implant survivorship of hip and knee replacements in the obese population.
Authors
- Nancy E. Lane (ORCID: https://orcid.org/0000-0002-0177-2198)
- Dongxing Xie (ORCID: https://orcid.org/0000-0003-2672-4544)
- Jie Wei (ORCID: https://orcid.org/0000-0003-3510-8241)
- Yuqing Zhang (ORCID: https://orcid.org/0000-0001-8142-8305)
- Martin Englund (ORCID: https://orcid.org/0000-0003-3320-2437)
- Xiaoxiao Li (ORCID: https://orcid.org/0000-0003-1612-0691)
- Guanghua Lei (ORCID: https://orcid.org/0000-0002-2468-3462)
- Chao Zeng (ORCID: https://orcid.org/0000-0003-0808-9807)
Institutions
- Harvard University (US)
- Central South University (CN)
- Hunan University (CN)
- Lund University (SE)
- Massachusetts General Hospital (US)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.61200
- Citations
- 5
- Primary Topic
- Total Knee Arthroplasty Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 10.03
Funders
- National Natural Science Foundation of China
- Central South University
- China Postdoctoral Science Foundation